Literature DB >> 25624160

Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer.

J-Y Lee1, T H Kim2, D H Suh3, J W Kim4, H S Kim1, H H Chung1, N H Park1, Y-S Song1, S B Kang5.   

Abstract

AIM: The aim of this study was to evaluate the effects of adherence to National Comprehensive Cancer Network (NCCN) guidelines on survival outcomes in patients with early-stage epithelial ovarian cancer.
METHODS: Our institutional cancer registry data on 266 patients with Stage I epithelial ovarian cancer was reviewed retrospectively and compliance with treatment guidelines for surgery and adjuvant treatment was determined. Patients were categorized according to adherence or non-adherence. The primary endpoints were recurrence-free survival and disease-specific survival. Hazard ratios (HRs) for survival were estimated with a Cox proportional hazards model.
RESULTS: Of the 266 patients, 71 (26.7%) underwent adequate surgical staging in accordance with the guidelines. The guidelines for adjuvant chemotherapy were followed adequately in all 71 patients that were adherent to surgical staging and in 163 of the 195 patients with non-adherence to surgical staging (83.6%). Multivariate analysis, adjusted for prognostic factors, identified higher recurrence-free survival (HR, 0.36; 95% CI, 0.15-0.88) and disease-specific survival (HR, 0.42; 95% CI, 0.16-1.12) among patients whose treatment adhered to both surgical and chemotherapy guidelines, although disease-specific survival was not statistically significant. When excluding clear cell histology from the cohort, the guideline-adherent group had significantly better disease-specific survival than the non-adherent group (HR, 0.13; 95% CI, 0.02-0.94).
CONCLUSION: The results of this study suggest that adherence to NCCN guidelines may improve survival outcomes in patients with early-stage epithelial ovarian cancer, particularly in cases other than clear cell histology.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant chemotherapy; Guideline adherence; Ovarian cancer; Surgical staging; Survival

Mesh:

Substances:

Year:  2015        PMID: 25624160     DOI: 10.1016/j.ejso.2015.01.006

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  13 in total

1.  Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.

Authors:  Young Shin Chung; Yun-Ji Kim; Inha Lee; Jung-Yun Lee; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

Review 2.  Ten Important Considerations for Ovarian Cancer Screening.

Authors:  Edward J Pavlik
Journal:  Diagnostics (Basel)       Date:  2017-04-13

3.  Changes in ovarian cancer survival during the 20 years before the era of targeted therapy.

Authors:  Jung-Yun Lee; Sunghoon Kim; Young Tae Kim; Myong Cheol Lim; Boram Lee; Kyu-Won Jung; Jae Weon Kim; Sang-Yoon Park; Young-Joo Won
Journal:  BMC Cancer       Date:  2018-05-29       Impact factor: 4.430

4.  Enhancing ovarian cancer care: a systematic review of guideline adherence and clinical variation.

Authors:  Kahren M White; Holly Seale; Reema Harrison
Journal:  BMC Public Health       Date:  2019-03-12       Impact factor: 3.295

5.  A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.

Authors:  Robert E Bristow; Jenny Chang; Carolina Villanueva; Argyrios Ziogas; Veronica M Vieira
Journal:  Obstet Gynecol       Date:  2020-02       Impact factor: 7.623

6.  Management of advanced ovarian cancer in Spain: an expert Delphi consensus.

Authors:  Andres Redondo; Ana Oaknin; Maria Jesus Rubio; Maria-Pilar Barretina-Ginesta; Ana de Juan; Luis Manso; Ignacio Romero; Cristina Martin-Lorente; Andres Poveda; Antonio Gonzalez-Martin
Journal:  J Ovarian Res       Date:  2021-05-26       Impact factor: 4.234

7.  Guideline-adherent treatment, sociodemographic disparities, and cause-specific survival for endometrial carcinomas.

Authors:  Victoria E Rodriguez; Alana M W LeBrón; Jenny Chang; Robert E Bristow
Journal:  Cancer       Date:  2021-03-15       Impact factor: 6.921

8.  Saudi lung cancer management guidelines 2017.

Authors:  Abdul Rahman Jazieh; Khaled Al Kattan; Ahmed Bamousa; Ashwaq Al Olayan; Ahmed Abdelwarith; Jawaher Ansari; Abdullah Al Twairqi; Turki Al Fayea; Khalid Al Saleh; Hamed Al Husaini; Nafisa Abdelhafiez; Mervat Mahrous; Medhat Faris; Ameen Al Omair; Adnan Hebshi; Salem Al Shehri; Foad Al Dayel; Hanaa Bamefleh; Walid Khalbuss; Sarah Al Ghanem; Shukri Loutfi; Azzam Khankan; Meshael Al Rujaib; Majed Al Ghamdi; Nagwa Ibrahim; Abdulmonem Swied; Mohammad Al Kayait; Marie Datario
Journal:  Ann Thorac Med       Date:  2017 Oct-Dec       Impact factor: 2.219

9.  Complications from Surgeries Related to Ovarian Cancer Screening.

Authors:  Lauren A Baldwin; Edward J Pavlik; Emma Ueland; Hannah E Brown; Kelsey M Ladd; Bin Huang; Christopher P DeSimone; John R van Nagell; Frederick R Ueland; Rachel W Miller
Journal:  Diagnostics (Basel)       Date:  2017-03-08

10.  Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers.

Authors:  Celine Montavon; Uzma Mirza; Andre Fedier; Andreas Schoetzau; Rosanna Zanetti Dällenbach; Viola Heinzelmann-Schwarz
Journal:  Exp Ther Med       Date:  2018-03-13       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.